Saturday, July 11, 2026

Drug profile · INN

garadacimab

garadacimab (ANDEMBRY) is an FDA-listed pharmaceutical active ingredient.

EMA: approved PMDA: approved Blood and blood forming organs (B06) B06AC07
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — garadacimab
Class
Blood and blood forming organs (B06)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

garadacimab (ANDEMBRY) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN garadacimab
Brand ANDEMBRY
Therapeutic class Blood and blood forming organs (B06)
ATC code B06AC07

Approval history

Authority Status Date
EMA approved
PMDA approved

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is garadacimab?

garadacimab (ANDEMBRY) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for garadacimab?

ANDEMBRY is a marketed brand name for garadacimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.